Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression

E-cadherin is involved in cell–cell adhesion and epithelial-to-mesenchymal transitions. In cancers, loss or inactivation of E-cadherin is associated with epithelial cell proliferation and invasion. Here, we sought to determine, if risk associations for 18 breast cancer susceptibility single nucleotide polymorphisms (SNPs) differed by E-cadherin tumor tissue expression in the Polish Breast Cancer Study (PBCS), using data on 1,347 invasive breast cancer cases and 2,366 controls. E-cadherin expression (low/high) was assessed using immunohistochemical staining of tumor tissue microarrays. Replication data on 2,006 cases and 6,714 controls from the Study of Epidemiology and Risk Factors in Cancer Heredity was used to follow-up promising findings from PBCS. In PBCS, we found the rs11249433 SNP at the 1p11.2 locus to be more strongly associated with risk of E-cadherin low tumors (OR = 1.30, 95 % CI = 1.08–1.56) than with E-cadherin high tumors [OR = 1.06, 95 % CI = 0.95–1.18; case-only p-heterogeneity (p-het) = 0.05]. Findings in PBCS for rs11249433 were replicated in SEARCH. Combined analyses of the two datasets for SNP rs11249433 revealed significant heterogeneity by E-cadherin expression (combined case-only p-het = 0.004). Further, among carriers of rs11249433, the highest risk was seen for E-cadherin low tumors that were ER-positive and of lobular histology. Our results in two independent data sets suggest that rs11249433, which is located between the NOTCH2 and FCGR1B genes within the 1p11.2 locus, is more strongly associated with risk of breast tumors with low or absent E-cadherin expression, and suggest that evaluation of E-cadherin tumor tissue expression may be useful in clarifying breast cancer risk factor associations.

[1]  B. Győrffy,et al.  Identification of a claudin‐4 and E‐cadherin score to predict prognosis in breast cancer , 2011, Cancer science.

[2]  Patrick Neven,et al.  Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.

[3]  M. Colleoni,et al.  Adjuvant therapies for special types of breast cancer. , 2011, Breast.

[4]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[5]  C. Caldas,et al.  Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance , 2011, Breast Cancer Research.

[6]  Michael Jones,et al.  Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.

[7]  Peter Kraft,et al.  Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status , 2012, Journal of Medical Genetics.

[8]  W. Birchmeier,et al.  Role of morphogenetic factors in metastasis of mammary carcinoma cells , 1998, Oncogene.

[9]  M. García-Closas,et al.  Established breast cancer risk factors by clinically important tumour characteristics , 2006, British Journal of Cancer.

[10]  C. Shapiro,et al.  Stem cell-related markers in primary breast cancers and associated metastatic lesions , 2012, Modern Pathology.

[11]  M. García-Closas,et al.  Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. , 2007, Cancer research.

[12]  S. Shousha,et al.  Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. , 1998, Journal of clinical pathology.

[13]  Montserrat Garcia-Closas,et al.  Genetic susceptibility to breast cancer , 2010, Molecular oncology.

[14]  Gerhard Christofori,et al.  A causal role for E-cadherin in the transition from adenoma to carcinoma , 1998, Nature.

[15]  A. Børresen-Dale,et al.  NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations , 2010, Molecular Cancer.

[16]  Manolis Kellis,et al.  HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants , 2011, Nucleic Acids Res..

[17]  S. Pinder,et al.  E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significance , 2005, Histopathology.

[18]  M. García-Closas,et al.  Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[19]  F. Vicini,et al.  Clinicopathologic implications of E‐cadherin reactivity in patients with lobular carcinoma in situ of the breast , 2001, Cancer.

[20]  Patrick Neven,et al.  Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) , 2012, PloS one.

[21]  Carlos Caldas,et al.  Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer , 2009, International journal of cancer.

[22]  T. Rebbeck,et al.  Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. , 2001, American journal of clinical pathology.

[23]  J. Visvader,et al.  Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. , 2008, Cell stem cell.

[24]  W. Willett,et al.  A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.

[25]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[26]  Peter Kraft,et al.  A Genome-Wide Association Study of Prognosis in Breast Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[27]  Frank McCormick,et al.  Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. , 2004, Genes & development.

[28]  Wei Zheng,et al.  Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. , 2011, The Lancet. Oncology.